跳转至内容
Merck
所有图片(1)

主要文件

89922

Supelco

元素杂质混标2,符合ICH Q3D注射用

TraceCERT®, (in 10% hydrochloric acid), applicable for testing acc. to USP<232>, Ph.Eur. Gen. Chapter 5.20

别名:

ICH Q3D Elemental Impurity Standard 2

登录查看公司和协议定价


About This Item

分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material
TraceCERT®

品質等級

agency

according to ICH Q3D
according to Ph. Eur.
according to USP

產品線

TraceCERT®

儲存期限

limited shelf life, expiry date on the label

成份

Au, 100 mg/L
Ir, 10 mg/L
Os, 10 mg/L
Pd, 10 mg/L
Pt, 10 mg/L
Rh, 10 mg/L
Ru, 10 mg/L

濃度

(in 10% hydrochloric acid)

技術

ICP: suitable

形式

multi-component solution

一般說明

This certified reference material (CRM) is produced and certified in accordance with ISO/IEC 17025 and ISO 17034. This CRM is traceable to SI unit kg and measured against primary material from an NMI, e.g. NIST.
Certified content incl. uncertainty and expiry date are given on the certificate.
Download your certificate at: http://www.sigma-aldrich.com.

應用

<ul>
<li><strong>Determination of ICH-Q3D Elemental Impurity Leachables in Glass Vials:</strong> This study applies inductively coupled plasma mass spectrometry to assess ICH-Q3D elemental impurity leachables in glass vials used for parenteral applications, providing a crucial methodology for ensuring compliance with pharmaceutical heavy metal analysis standards (Breckenridge et al., 2023).</li>
<li><strong>Application of ICH Guidelines for Assessment and Control of Elemental Impurities in Parecoxib Sodium:</strong> Utilizing graphite-digestion and ICP-MS, this research conforms to the ICH Q3D guidelines for evaluating elemental impurities in parecoxib sodium, highlighting a robust approach for elemental impurity analysis in injectable pharmaceuticals (Hao et al., 2022).</li>
<li><strong>Risk-Based Approach to Evaluate and Control Elemental Impurities in Therapeutic Proteins:</strong> This study introduces a risk-based strategy for the assessment and control of elemental impurities in therapeutic proteins, which aligns with the requirements of USP &lt;232&gt; &lt;233&gt; compliance and aids in the development of safer parenteral medications (Luo et al., 2020).</li>
<li><strong>Assessment of Extractable Elements from Elastomers:</strong> Investigating the potential for elemental impurities to leach from elastomers, this research is vital for the risk assessment of elemental contaminants in parenteral formulations, ensuring safety and compliance with ICH Q3D standards (Paskiet et al., 2019).</li>
</ul>

準備報告

For the preparation of this CRM only materials of highest purity were used.

法律資訊

TraceCERT is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

象形圖

Corrosion

訊號詞

Warning

危險聲明

防範說明

危險分類

Met. Corr. 1

儲存類別代碼

8B - Non-combustible corrosive hazardous materials

水污染物質分類(WGK)

WGK 1


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Elemental impurities in drug products pose a risk to patient health due to toxicological effects, and their levels should be controlled within acceptable limits. Find analytical methods and materials for impurity assessment.

Elemental impurities in drug products pose a risk to patient health due to toxicological effects, and their levels should be controlled within acceptable limits. Find analytical methods and materials for impurity assessment.

Metallic contamination in drug products, referred to as elemental impurities, may arise from several sources

In 2009, the International Conference on Harmonization (ICH) proposed the development of a new harmonized guideline to provide a global policy for limiting metal impurities in drug products and ingredients. This approach provides clear regulatory guidance on specification limits for elemental impurities worldwide and logically should have an impact on the work of the national regulatory bodies in having transparent and comparable results.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门